Search

European regulators have approved the first therapy in the western world that can correct errors in a person’s genetic code, according to Amsterdam-based uniQure (formerly Amsterdam Molecular Therapeutics).

Europe has approved Glybera for treatment of Lipoprotein Lipase Deficiency (LPLD), a very rare, inherited disease. Patients with LPLD are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis).

Glybera introduces a normal, healthy LPL gene into the body so that it can make functional LPL protein. The LPL gene is packaged in a delivery vector derived from adeno-associated virus (AAV), serotype 1, which has a natural propensity towards muscle cells.

Glybera will be available in the second half of 2013, according to uniQure, which is preparing to apply for regulatory approval in the U.S., Canada, and other markets.

Source: http://www.kurzweilai.net/first-therapy-in-the-western-world-to-correct-errors-in-a-persons-genetic-code-approved



CHANGE THE LIVES OF MSUD ADULTS AND CHILDREN

The MSUD Family Support Group is currently funding several research projects and we are proactively looking for researchers interested in developing new treatments or finding a cure for MSUD. Significant funding is necessary if we are to accomplish this goal.
Donate Today Learn More

Subscribe to our mailing list

Signup To Our E-Blast Signup with your email address to receive our e-blast newsletter.